Understanding MET Alterations in Non‑Small Cell Lung Cancer and Emerging Targeted Treatment Options
The article outlines the primary MET alterations observed in non‑small cell lung cancer, focusing on gene amplification and exon 14 skipping mutations.
It explains that these MET changes frequently coexist with other oncogenic mutations, which can affect therapeutic choices.
Current and investigational targeted therapies directed at MET‑driven disease are reviewed, with an emphasis on how multidisciplinary tumor boards guide treatment selection.
The piece underscores the ongoing need for research to better identify patients who will benefit and to enhance clinical outcomes.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies”
read at onclive ↗
comments(0)
5-min edit window · permanent after that